R&D Platform

Seven programs. One regenerative thesis.

Our R&D platform is organised around a single belief: human biology can be rebuilt — not just patched — when regenerative tools are deployed at sovereign scale.

Each of our seven programs is designed to satisfy three filters: (1) deep clinical unmet-need, (2) sovereign-scale commercial logic for the U.S. ↔ GCC corridor, and (3) a translation pathway short enough to deliver real outcomes in this decade. We don't run science experiments — we run translation pipelines.

Our flagship hair-regeneration programme (iREY device + DAMI follicular delivery + exosome formulations) targets a $11B+ TAM and serves as the platform's commercial flywheel. The proceeds, IP architecture and clinical-trial capacity it generates fund our deeper programmes in organ bioengineering, rare-disease intelligence and women's regenerative health.

Programmes share a common operational substrate — the same regulatory team supports SFDA, FDA and DHA filings; the same omics-and-AI infrastructure powers everything from rare-disease registry analytics to follicle-selective drug discovery; and the same translational-commercialisation engine licenses platform IP into clinical, veterinary and longevity markets.

Active Programs

iREY · DAMI

Flagship Devices

$11B+

Hair Regen TAM

20+

Peer Publications

Research & Development Platform

Seven programs. One sovereign-scale regenerative platform.

From follicle-targeted hair regeneration to organ bioengineering and sovereign health intelligence — each program is built to translate research into clinical, commercial and national-capability impact.

01 / Phase I — Flagship

Patent-pending device · DAMI delivery · linked serum

iREY™ Multimodal Hair Regeneration

A patent-pending, multimodal regenerative platform pairing the iREY handheld device with our proprietary DAMI delivery architecture and a bioactive serum ecosystem — engineered for clinical and at-home use, with a built-in subscription pathway for consumable cartridges. Targets a global hair-restoration market exceeding $11B.

iREY handheld device platform
DAMI follicular delivery technology
Exosome-based regenerative serums
Subscription-based treatment & service model

02 / Pharma Asset

Follicle-selective androgen signaling modulators

Precision Drug Discovery

A novel pharmacological program targeting follicle-selective androgen signaling — a high-value pharma licensing opportunity offering comparable efficacy to standard-of-care therapies (Finasteride / Dutasteride) with significantly reduced systemic exposure and side-effect profile.

Cofactor-selective AR modulation
Biomarker-guided follicular targeting
Localized, follicle-specific delivery
Pharma licensing & out-partnering opportunity

Sovereign Health Data & Rare Disease Intelligence

03 / Sovereign Data

GCC-wide registry · genomics · AI

Sovereign Health Data & Rare Disease Intelligence

A sovereign, multi-country health-data and clinical-intelligence platform organizing rare-disease populations, standardizing clinical data and enabling trial-ready healthcare ecosystems across Saudi Arabia, the UAE and Qatar — operating under national governance frameworks with Ministries of Health.

National rare-disease registries
Natural-history & cohort data
Trial-readiness for global pharma
Genomics + AI precision-health insights

04 / Mid-Term Translational

Implant-free · biologically integrated

Regenerative Breast & Women's Health

A next-generation regenerative breast-reconstruction and augmentation platform — designed to transition the field from implant-based and fat-grafting approaches toward implant-free, biologically integrated, minimally invasive solutions across a multi-billion-dollar global market.

Stem-cell-enriched autologous adipose platforms
Biosynthetic & acellular dermal matrices
Scar-sparing trans-axillary access systems
Future oncology biologics (incl. triple-negative)

05 / Long-Term Flagship

Micro-livers · organogenesis · bioreactors

Liver & Organ Bioengineering

Hepatic regeneration, micro-liver validation systems and progressive organogenesis — a long-term strategic pillar positioning participating GCC nations at the forefront of global regenerative biotechnology and organ engineering.

Hepatic regeneration & precision therapeutics
Micro-liver validation & screening systems
Progressive organogenesis pipeline
Future organ-replacement science

06 / Longevity

Mitochondrial · regenerative wellness

Biohacking & Anti-Aging

Longevity medicine, mitochondrial health programs and premium regenerative wellness — a future-facing health-concierge layer for the next decade of human performance.

Longevity medicine
Mitochondrial health
Regenerative wellness
Premium future-health programs

Translational Commercialization & Biotech Deployment

07 / Day-One Revenue

Licensing · white-label · GCC deployment

Translational Commercialization & Biotech Deployment

An immediate revenue and market-activation engine — strategic licensing, white-label commercialization and rapid deployment across human, veterinary and longevity-focused applications. Initial focus: next-generation stem-cell-based regenerative products for orthopedics, sports medicine and high-performance animal care.